Pneumocystis pneumonia remains one of the leading causes of morbidity and mortality in the HIV-infected population. Trimethoprim-sulfamethoxazole remains the drug of choice for both the treatment and prevention of this infection, although a high rate of side effects in HIV-infected patients often necessitates alternative treatment regimens. This article will review pneumocystis pneumonia, with a focus on the various therapeutic options, their side effects, and the immune reconstitution inflammatory syndrome as it relates to pneumocystis pneumonia infection.
Jain MK, Skiest DJ, Cloud JW, Jain CL, Burns D, Berggren RE. Changes in mortality related to human immunodeficiency virus infection: comparative analysis of inpatient deaths in 1995 and in 1999-2000. Clin Infect Dis.2003;36:1030-1038.
2.
Chagas C. Nova tripanosomiaze humana. Mem Inst Oswaldo Cruz.1909;1:159-218.
3.
Edman JC, Kovacs JA, Masur H, Santi DV, Elwood HJ, Sogin ML. Ribosomal RNA sequence shows Pneumocystis cariniito be a member of the fungi. Nature. 1988;334:519-5222.
4.
Stringer SL, Stringer JR, Blaser MA, Walzer PD, Cushion MT. Pneumocystis carinii: sequence from ribosomal RNA implies a close relationship with fungi. Exp Parasitol. 1989;68:450-461.
5.
Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jiroveci) for Pneumocystisfrom humans. Emerg Infect Dis.2002;8:891-896.
6.
Walzer PD, Perl DP, Krogstad DJ, et al. Pneumocystis carinii pneumonia in the United States. Ann Intern Med.1974;80:83-93.
7.
Pifer LL, Hughes WT, Stagno S, Woods D. Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children. Pediatrics. 1978;61:35-41.
8.
Wakefield AE, Pixley FJ, Banerji S, et al. Detection of Pneumocystis cariniiwith DNA amplification. Lancet. 1990;336:451-453.
9.
Keely SP, Stringer JR. Sequences of Pneumocystis cariniif. sp. Hominis strains associated with recurrent pneumonia vary at multiple loci. J Clin Microbiol. 1997;35:2745-2747.
10.
Keely SP, Stringer JR, Baughman RP, Linke MJ, Walzer PD, Smulian AG. Genetic variation among Pneumocystis carinii hominis isolates in recurrent pneumoncystosis. J Infect Dis.1995;172:595-598.
11.
Manoloff ES, Francioli P, Taffe P, vanMelle G, Bille J, Hauser PM. Risk for Pneumocystis cariniitransmission among patientswith pneumonia: a molecular epidemiology study. Emerg Infect Dis.2003;9:132-134.
12.
Phair J, Munoz A, Detels R, et al. The risk of Pneumocystis cariniipneumonia amongmen infected with human immunodeficiency virus type 1. N Engl J Med.1990;322:161-165.
13.
Kovacs JA, Gill VJ, Meshnick S, Masur H. New insights into transmission, diagnosis, and drug treatment of Pneumocystis cariniipneumonia. JAMA. 2001;286:2450-2460.
14.
Willocks L, Burns S, Cossar R, Brettle R. Diagnosis of Pneumocystis cariniipneumonia in a population of HIV-positive drug users, with particular reference to sputum and fluorescent antibody techniques. J Infect. 1993;26:257-264.
15.
Kroe DM, Kirsch CM, Jensen WA. Diagnostic strategies for Pneumocystis cariniipneumonia. Semin Respir Infect. 1997;12:70-78.
16.
Jules-Elysee KM, Stover DE, Zaman MB, Bernard EM, White DA. Aerosolized pentamidine: effect on diagnosis and presentation of Pneumocystis cariniipneumonia. Ann Intern Med.1990;112:750-757.
17.
Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. Clin Infect Dis.2005;40:S131-S235.
18.
Wharton JA, Coleman DL, Wofsy CB, et al. Trimethoprimsulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Ann Intern Med.1986;105:37-44.
19.
Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patientswith advanced human immunodeficiency virus infection. N Engl J Med.1995;332:693-699.
20.
Sattler FR, Cowan R, Nielsen DM, Ruskin J. Trimethoprimsulfamethoxazole compared with pentamidine for treatment of Pneumocystis cariniipneumonia in the acquired immunodeficiency syndrome. Ann Intern Med.1988;109:280-287.
21.
Safrin S, Finkelstein DM, Feinberg J, et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. Ann Intern Med.1996;124:792-802.
22.
Kovacs JA, Hiemenz JW, Macher AM, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med.1984;100:663-671.
23.
Gordon FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med.1984;100:495-499.
24.
Leoung GS, Stanford JF, Giordano MF, et al. Trimethoprimsulfamethoxazole (TMP-SMX) dose escalation versus direct rechallenge for Pneumocystis cariniipneumonia prophylaxis in human immunodeficiency virus-infected patients with previous adverse reaction to TMP-SMX. J Infect Dis.2001;184:992-997.
25.
Gluckstein D, Ruskin J. Rapid oral desensitization to trimethoprim-sulfamethoxazole (TMP-SMX): use in prophylaxis for Pneumocystis cariniipneumonia in patientswith AIDS who were previously intolerant too TMP-SMX. Clin Infect Dis.1995;20:849-853.
26.
Edman JC, Edman U, Cao M, et al. Isolation and expression of the Pneumocystis cariniidihydrofolate reductase gene. Proc Natl Acad Sci U S A. 1989;86:8625-8629.
27.
Lane BR, Ast JC, Hossler PA, et al. Dihydropteroate synthase polymorphisms in Pneumocystis carinii. J Infect Dis.1997;175:482-485.
28.
Kazanjian P, Armstrong W, Hossler PA, et al. Pneumocystis cariniimutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients. J Infect Dis.2000;182:551-557.
29.
Smego RA, Nagar S, Maloba B, Mirjana P. Ameta-analysis of salvage therapy for Pneumocystis cariniipneumonia. Arch Intern Med.2001;161:1529-1533.
30.
Noskin GA, Murphy RL, Black JR, Phair JP. Salvage therapywith clindamycin/primaquine for Pneumocystis cariniipneumonia. Clin Infect Dis.1992;14:183-188.
31.
Medina I, Mills J, Leoung G, et al. Oral therapy for Pneumocystis cariniipneumonia in the acquired immunodeficiency syndrome. N Engl J Med.1990;323:776-782.
32.
Mills J, Leong G, Medina I, et al. Dapsone treatment of Pneumocystis cariniipneumonia in the acquired immunodeficiency syndrome. Antimicrob Agents Chemother. 1988;32:1057-1060.
33.
Rosenberg DM, McCarthy W, Slavinsky J, et al. Atovaquone suspension for treatment of Pneumocystis cariniipneumonia in HIV-infected patients. AIDS. 2001;26:211-214.
34.
Sattler FR, Frame P, Davis R, et al. Trimetrexate with leucovorin versus trimethoprim-sulfamethoxazole for moderate to severe episodes of Pneumocystis cariniipneumonia in patients with AIDS: a prospective, controlled multicenter investigation of the AIDS clinical trials group protocol 029/031. J Infect Dis.1994;170:165-172.
35.
Montanter JSG, Lawson LM, Levitt N, Belzberg A, Schecter MT, Ruedy J. Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis cariniipneumonia and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med.1990;113:14-20.
36.
Gagnon S, Boota AM, Fischl MA, Baier H,Kirksey OW, La Voie L. Corticosteroids as adjunctive therapy for severe Pneumocystis cariniipneumonia in the acquired immunodeficiency syndrome. N Engl J Med.1990;323:1444-1450.
37.
Bozzette SA, Sattler FR, Chiu J, et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis cariniipneumonia in the acquired immunodeficiency syndrome. N Engl J Med.1990;323:1451-1457.
38.
Masur H, Meier P, McCutchan JA, et al. Special report: consensus statement on the use of corticosteroids as adjunctive therapy for Pneumocystispneumonia in the acquired immunodeficiency syndrome. N Engl J Med.1990;323:1500-1504.
39.
Shelburne SA, Hamill RJ, Rodriguez-Barradas MC, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine. 2002;81:213-227.
40.
French MA, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med.2000;1:107-115.
41.
Barry SM, Lipman MC, Deery AR, et al. Immune reconstitution pneumonitis following Pneumocystis cariniipneumonia in HIV-infected subjects. HIV Med.2002;3:207-211.
42.
Koval CE, Gigliotti F, Nevins D, Demeter LM. Immune reconstitution syndrome after successful treatment of Pneumocystis cariniipneumonia in aman with human immunodeficiency virus type 1 infection. Clin Infect Dis.2002;35:491-493.
